DPPA3

Chr 12

developmental pluripotency associated 3

Also known as: Pgc7, STELLA

The protein functions in epigenetic chromatin reprogramming during early embryonic development, specifically protecting maternal genome DNA methylation by binding to H3K9me2 histone marks and preventing demethylation in the zygote. Mutations cause developmental and epileptic encephalopathy with microcephaly and corpus callosum hypoplasia, with inheritance following an autosomal recessive pattern. The gene shows moderate tolerance to loss-of-function variants (LOEUF 0.89), consistent with the recessive inheritance pattern observed in affected patients.

Summary from RefSeq, UniProt
Research Assistant →
0
Active trials
10
Pubs (1 yr)
44
P/LP submissions
0%
P/LP missense
0.89
LOEUF
Multiple*
Mechanism· predicted
Clinical SummaryDPPA3
Population Constraint (gnomAD)
Constrained for loss-of-function variants (OE-LoF 0.28) despite low pLI — interpret in context.
📋
ClinVar Variants
43 unique Pathogenic / Likely Pathogenic· 36 VUS of 85 total submissions

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint
0.89LOEUF
pLI 0.217
Z-score 1.76
OE 0.28 (0.120.89)
Tolerant

Typical tolerance to LoF variation

Missense Constraint
-0.25Z-score
OE missense 1.08 (0.911.27)
97 obs / 90.2 exp
Tolerant

Tolerant to missense variation

Observed / Expected Ratios
LoF OE0.28 (0.120.89)
00.351.4
Missense OE1.08 (0.911.27)
00.61.4
Synonymous OE1.00
01.21.6
LoF obs/exp: 2 / 7.1Missense obs/exp: 97 / 90.2Syn Z: 0.01
DN
0.79top 25%
GOF
0.84top 5%
LOF
0.1697th %ile

This gene has evidence for multiple mechanisms of pathogenicity (gain-of-function and dominant-negative). Both the Badonyi & Marsh prediction and the broader genomic evidence point to gain-of-function as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

GOFprediction above median
DNprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

85 submitted variants in ClinVar

Classification Summary

Pathogenic41
Likely Pathogenic2
VUS36
Likely Benign4
41
Pathogenic
2
Likely Pathogenic
36
VUS
4
Likely Benign

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
41
0
41
Likely Pathogenic
0
0
2
0
2
VUS
0
27
9
0
36
Likely Benign
0
3
1
0
4
Benign
0
0
0
0
0
Total03053083

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

DPPA3 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →
Clinical Literature
Open Research Assistant →